+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Global Human Microbiome Therapeutics market set to grow to $1bn by 2024” says new Visiongain report

24 April 2019
Pharma

Visiongain has published a new pharma report Human Microbiome Therapeutics Market Report : Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders.

A specialist sector within the overall pharmaceutical industry, the human microbiome-therapeutic market is dominated by a relatively small number of companies. The market holds enormous opportunities for growth in key therapeutic areas. Some of the Phase III drugs are expected to be launched in the first half of the forecast period while few Phase II drugs are expected to be launched in second half of the forecast period. We expect growth in all key sectors of the market during the forecast period.

This report profiled the selected companies: 4D Pharma, AOBiome Therapeutics, C3J Therapeutics, Caelus Health, Enterome Bioscience, Ferring Pharmaceuticals, Finch Therapeutics/Crestovo, IGEN BIOTECH GROUP, Immuron, Intrexon Corporation, MaaT Pharma, MatriSys Biosystem and other companies.

The lead analyst commented that "The prime opportunity for microbiome therapeutics is to fulfil the unmet clinical needs in various indications. The current therapies in some of the indication may provide symptomatic relief but cannot cure the disease or have adverse side effects. The microbiome industry is in nascent stage but developing rapidly. The first human microbiome therapeutics is expected to launch in 2020. Various clinical data suggests that the use of microbiome-based therapies is likely to cause fewer side effects than the use of traditional pharmaceuticals, further enhancing their market potential."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

23 April 2024

Read

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read